Details
Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration for the treatment of mild to moderate COVID-19. CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from treatment with Evusheld.